FDA ap­proves San­doz’s na­tal­izum­ab biosim­i­lar, like­ly putting a damper on Bio­gen’s Tysabri sales

On the back of San­doz’s FDA ap­proval for the first-ever na­tal­izum­ab biosim­i­lar, brand­ed as Tyruko, Bio­gen now has a for­mi­da­ble mul­ti­ple scle­ro­sis mar­ket com­peti­tor for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER